Methods for facilitating metabolic control

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S835000, C514S866000

Reexamination Certificate

active

07732478

ABSTRACT:
The present invention provides methods for facilitating metabolic control in a subject by decreasing the level of Il-1β in the GCF. The present invention further provides methods for decreasing the level of circulating TNF in a subject. Also provided are uses of anti-inflammatory agents in these methods.

REFERENCES:
patent: 5464609 (1995-11-01), Kelm et al.
patent: 5646174 (1997-07-01), Kelm et al.
patent: 5785951 (1998-07-01), Kelm et al.
patent: 5962030 (1999-10-01), Fine
patent: 0 519 983 (1996-05-01), None
patent: WO 2008042944 (2008-04-01), None
Brownlee et al., Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications, N. Eng. J. Med., 318:1315-1321, 1988.
Morohoshi, M. et al., Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes, 45:954-959, 1996.
Esposito, K. et al., Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation, 106:2067-2072, 2002.
Schmidt, A.M. et al., Cellular receptors for advanced glycation end products. Arterioscler. Thromb., 14:1521-1528, 1994.
Fernandez-Real, J.M. et al., Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr. Rev., 24:278-301, 2003.
Duncan, B.B. et al., Factor VIII and other hemostasis variables are related to incident diabetes in adults. Diabetes Care, 22:767-772, 1999.
Cavanaugh, Jr., P.F. et al., Coordinate production of PGE2 and IL-1 beta in the gingival crevicular fluid of adults with periodontitis: its relationship to alveolar bone loss and disruption by twice daily treatment with ketorolac tromethamine oral rinse. J. Periodontal Res. 33:75-82, 1998.
Schmidt, A. M. et al., The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Investigation, 108(7):949-955, 2001.
Bierhaus, A. et al., Diabetes-associated sustained activation of the transcription factor nuclear factor-kB. Diabetes, 50:2792-2808, 2001.
Cutler et al., Heightened gingival inflammation and attachment loss in type 2 diabetics with hyperlipidemia. J. Periodontal., 70: 1313-1321, 1999.
Engebretson et al., The Influence of interleukin gene polymorphism on expression of interleukin-1 beta and tumor necrosis factor alpha in periodontal tissue and gingival crevicular fluid. J. Periodontal, 70: 567-573, 1999.
Engebretson et al., GCF IL-1 beta profiles in periodontal disease. J. Clin. Peridontol., 29: 48-53, 2002.
Emrich et al., Periodontal disease in non-insulin-dependent diabetes mellitus. J. Periodontol., 62: 123-131, 1991.
Figueredo et al., Increased interleukin-1 beta concentration in gingival crevicular fluid as a characteristic of periodontitis. J. Periodontol., 70: 1457-1463, 1999.
Gowen and Mundy, Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J. Immunol., 136: 2478-2482, 1986.
Hou et al., Crevicular Interleukin-1 beta in moderate and severe periodonitis patients and the effect of phase I periodontal treatment. J. Clin. Periodontol., 22: 162-67 1995.
Kurtis et al., IL-6 levels in gingival crevicular fluid (GCF) from patients with non-insulin dependent diabetes mellitus (NIDDM), adult periodontitis and healthy subjects. J. Oral Sci., 41: 163-167, 1999.
Lamster et al., A comparison of 4 methods of data presentation for lysosomal enzyme activity in gingival crevicular fluid. J. Clin. Periodontol., 15: 347-352, 1988.
Lamster et al., Correlation analysis for clinical and gingival crevicular fluid parameters at anatomically related gingival sites. J. Clin. Periodontol., 18: 272-277, 1991.
Losche et al., Plasma lipid and blood glucose levels in patients with destructive periodontal disease. J. Clin. Periodontol., 27: 537-541, 2000.
Masada et al., Measurement of interleukin-1 alpha and -1 beta in gingival crevicular fluid: implications for the pathogenesis of periodontal disease. J. Periodontal Res., 25: 156-163, 1990.
Mathur et al., Interleukin-1 alpha, interleukin-8 and interferon-alpha levels in gingival crevicular fluid. J. Periodontal Res., 31: 489-495, 1996.
Oliver and Tervonen, Periodontitis and tooth loss: comparing diabetics with the general population. J. Am. Dent. Assoc., 124: 71-76, 1993.
Oringer et al., Effect of locally delivered minocycline microspheres on markers of bone resorption. J. Periodontol., 73: 835-842, 2002.
Salvi et al., Inflammatory mediator response as a potential risk marker for periodontal diseases in insulin-dependent diabetes mellitus patients. J. Periodontol., 68: 127-135, 1997.
Salvi et al., PGE2, IL-1 beta, and TNF-alpha responses in diabetics as modifiers of periodontal disease expression. Ann. Periodontol., 3: 40-50, 1998.
Schmidt et al., Advanced glycation endproducts (AGEs) induce oxidant stress in the gingival: a potential mechanism underlying accelerated periodontal disease associated with diabetes. J. Periodontal Res., 31:508-515, 1996.
Schmidt et al., Elevated plasma levels of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: a marker of vascular dysfunction and progressive vascular disease. Br. J. Haematol., 92: 747-750, 1996.
Schmidt et al., RAGE: a novel cellular receptor for advanced glycation end products. Diabetes, 45: S77-S80, 1996.
Soskolne and Klinger, The relationship between periodontal diseases and diabetes: an overview. Ann. Periodontol., 6: 91-98, 2001.
Stashenko et al., Tissue levels of bone resorptive cytokines in periodontal disease. J. Periodontal., 62: 504-509, 1991.
Taylor et al., Severe periodontitis and risk for poor glycemic control in patients with non-insulin-dependent diabetes mellitus. J. Periondontol., 67: 1085-1093, 1996.
Taylor et al., Impact of oral diseases on systemic health in the elderly: diabetes mellitus and aspiration pneumonia. J. Public Health Dent., 60: 313-320, 2000.
Tervonen and Knuuttila, Relation of diabetes control to periodontal pocketing and alveolar bone level. Oral Surg. Oral Med. Oral Pathol., 61: 346-349. 1986.
Tervonen et al, Prevalence of periodontal pathogens with varying metabolic control of diabetes mellitus. J. Clin. Periodontol., 21: 375-379, 1994.
Tsai et al., Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent. Oral Epidemiol., 30: 182-192, 2002.
Vlassara et al., Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science, 240: 1546-1548, 1988.
Yan et al., Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem., 269: 9889-97, 1994.
Yuan et al., Detection of putative periodontal pathogens in non-insulin-dependent diabetes mellitus and non-diabetes mellitus by polymerase chain reaction. J. Periodontal Res., 36: 18-24, 2001.
Zambon et al., Microbiological and immunological studies of adult periodontitis in patients with noninsulin-dependent diabetes mellitus. J. Periodontol., 59: 23-31, 1988.
Al-Mubarak, et al., “Comparative evaluation of adjunctive oral irrigation in diabetics,” J. Clin Periodontal 2002; 29: 295-300.
Ostrov, C.S. et al., “Keterolac, Prednisolone, and Dexamethasone for Postoperative Inflammation,” Clin. Therapeut., 1997, vol. 19, No. 2, pp. 259-272.
Nishimura, F. et al., “Periodontal Inflammation and Insulin Resistance-Lessons from Obesity” J. Dent. Res., Aug. 2001, vol. 80, No. 8, pp. 1690-1694.
Grossi, S.G., “Treatment of Periodontal Disease and Control of Diabetes: An Assessment of the Evidence and Need for Future Research,” Ann. Periodontol, Dec. 2001, vol. 6, No. 6, pp. 138-145.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods for facilitating metabolic control does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for facilitating metabolic control, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for facilitating metabolic control will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4242310

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.